Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis

Mauro Viganò, Massimo Colombo, Adriana Aroldi, Giovanna Lunghi, Elena Manenti, Claudio Ponticelli, Pietro Lampertico

Research output: Contribution to journalArticle

Abstract

Background: Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis. Methods: Seventeen such patients [median age: 45 years; 7 with hepatitis B e antigen (HBeAg)] received daily oral doses of 75-150 mg lamivudine for a median of 48 (range 11-81) months. All patients had baseline serum levels of HBV DNA of over 6 log 10 copies per ml and of alanine transaminase (ALT) of over 1.5 times the upper normal limit (UNL). Clinical lamivudine resistance was defined as a rebound of serum HBV DNA above 5.3 log 10 copies per ml and of serum ALT of over 1.5 times the UNL in patients who initially responded with HBV DNA levels of less than 5.3 log 10 copies per ml and normal ALT values. Controls were 14 renal-transplant patients (median age 44 years; 3 with HBeAg) with HBV-related cirrhosis, naive to any anti-HBV therapy, followed for 58 months (4-135). Results: Thirteen (77%) treated patients had a persistent response throughout the study period, including three (18%) who developed genotypic resistance, compared with none of the untreated controls (77% versus 0%, P

Original languageEnglish
Pages (from-to)709-713
Number of pages5
JournalAntiviral Therapy
Volume10
Issue number6
Publication statusPublished - 2005

Fingerprint

Lamivudine
Hepatitis B
Hepatitis B virus
Fibrosis
Kidney
Alanine Transaminase
Hepatitis B e Antigens
DNA
Serum
Chronic Hepatitis B
Virus Diseases
Transplant Recipients
Morbidity
Transplants
Safety
Mortality

ASJC Scopus subject areas

  • Pharmacology

Cite this

Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. / Viganò, Mauro; Colombo, Massimo; Aroldi, Adriana; Lunghi, Giovanna; Manenti, Elena; Ponticelli, Claudio; Lampertico, Pietro.

In: Antiviral Therapy, Vol. 10, No. 6, 2005, p. 709-713.

Research output: Contribution to journalArticle

Viganò, Mauro ; Colombo, Massimo ; Aroldi, Adriana ; Lunghi, Giovanna ; Manenti, Elena ; Ponticelli, Claudio ; Lampertico, Pietro. / Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis. In: Antiviral Therapy. 2005 ; Vol. 10, No. 6. pp. 709-713.
@article{c7ea7755797c49f198f8c3c14a63d620,
title = "Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis",
abstract = "Background: Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis. Methods: Seventeen such patients [median age: 45 years; 7 with hepatitis B e antigen (HBeAg)] received daily oral doses of 75-150 mg lamivudine for a median of 48 (range 11-81) months. All patients had baseline serum levels of HBV DNA of over 6 log 10 copies per ml and of alanine transaminase (ALT) of over 1.5 times the upper normal limit (UNL). Clinical lamivudine resistance was defined as a rebound of serum HBV DNA above 5.3 log 10 copies per ml and of serum ALT of over 1.5 times the UNL in patients who initially responded with HBV DNA levels of less than 5.3 log 10 copies per ml and normal ALT values. Controls were 14 renal-transplant patients (median age 44 years; 3 with HBeAg) with HBV-related cirrhosis, naive to any anti-HBV therapy, followed for 58 months (4-135). Results: Thirteen (77{\%}) treated patients had a persistent response throughout the study period, including three (18{\%}) who developed genotypic resistance, compared with none of the untreated controls (77{\%} versus 0{\%}, P",
author = "Mauro Vigan{\`o} and Massimo Colombo and Adriana Aroldi and Giovanna Lunghi and Elena Manenti and Claudio Ponticelli and Pietro Lampertico",
year = "2005",
language = "English",
volume = "10",
pages = "709--713",
journal = "Antiviral Therapy",
issn = "1359-6535",
publisher = "International Medical Press Ltd",
number = "6",

}

TY - JOUR

T1 - Long-term lamivudine monotherapy in renal-transplant recipients with hepatitis-B-related cirrhosis

AU - Viganò, Mauro

AU - Colombo, Massimo

AU - Aroldi, Adriana

AU - Lunghi, Giovanna

AU - Manenti, Elena

AU - Ponticelli, Claudio

AU - Lampertico, Pietro

PY - 2005

Y1 - 2005

N2 - Background: Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis. Methods: Seventeen such patients [median age: 45 years; 7 with hepatitis B e antigen (HBeAg)] received daily oral doses of 75-150 mg lamivudine for a median of 48 (range 11-81) months. All patients had baseline serum levels of HBV DNA of over 6 log 10 copies per ml and of alanine transaminase (ALT) of over 1.5 times the upper normal limit (UNL). Clinical lamivudine resistance was defined as a rebound of serum HBV DNA above 5.3 log 10 copies per ml and of serum ALT of over 1.5 times the UNL in patients who initially responded with HBV DNA levels of less than 5.3 log 10 copies per ml and normal ALT values. Controls were 14 renal-transplant patients (median age 44 years; 3 with HBeAg) with HBV-related cirrhosis, naive to any anti-HBV therapy, followed for 58 months (4-135). Results: Thirteen (77%) treated patients had a persistent response throughout the study period, including three (18%) who developed genotypic resistance, compared with none of the untreated controls (77% versus 0%, P

AB - Background: Chronic hepatitis B virus (HBV) infection is an important cause of morbidity and mortality in renal-transplant recipients. The aim of the study was to assess the efficacy and safety of long-term lamivudine monotherapy in renal-transplant recipients with HBV-related cirrhosis. Methods: Seventeen such patients [median age: 45 years; 7 with hepatitis B e antigen (HBeAg)] received daily oral doses of 75-150 mg lamivudine for a median of 48 (range 11-81) months. All patients had baseline serum levels of HBV DNA of over 6 log 10 copies per ml and of alanine transaminase (ALT) of over 1.5 times the upper normal limit (UNL). Clinical lamivudine resistance was defined as a rebound of serum HBV DNA above 5.3 log 10 copies per ml and of serum ALT of over 1.5 times the UNL in patients who initially responded with HBV DNA levels of less than 5.3 log 10 copies per ml and normal ALT values. Controls were 14 renal-transplant patients (median age 44 years; 3 with HBeAg) with HBV-related cirrhosis, naive to any anti-HBV therapy, followed for 58 months (4-135). Results: Thirteen (77%) treated patients had a persistent response throughout the study period, including three (18%) who developed genotypic resistance, compared with none of the untreated controls (77% versus 0%, P

UR - http://www.scopus.com/inward/record.url?scp=25444524337&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444524337&partnerID=8YFLogxK

M3 - Article

C2 - 16218169

AN - SCOPUS:25444524337

VL - 10

SP - 709

EP - 713

JO - Antiviral Therapy

JF - Antiviral Therapy

SN - 1359-6535

IS - 6

ER -